Additional Plavix Information Today physicians managing patients with an acute coronary syndrome (ACS) have a choice among three oral products intended to reduce the risk of thrombotic events by decreasing platelet aggregation. Additional Plavix Information. Plavix Drug Interactions Center clopidogrel oral. Plavix FDA Approved Prescribing Information including Dosage.
Gluconorm repaglinide - New Contraindication for Concomitant. These drugs are clopidogrel (Plavix, approved by the FDA in 1997), prasugrel (Effient, approved in 2009), and ticagrelor (Brilinta, approved in 2011). The concomitant use of repaglinide and clopidogrel is now. This information has now led to new prescribing information in the CPM for.
Warning diminished antiplatelet effect in patients with Unstable angina, non-ST-segment elevation MI (NSTEMI): 300 mg loading dose; initiating therapy without a loading dose will delay establishment of antiplatelet effect by several days; following the loading dose, administer 75 mg/day PO for up to 12 months; may administer beyond 12 months if used in combination with aspirin (75-100 mg/day); long-term combination therapy with aspirin, following stent placement, is individualized depending on how a patient tolerates long-term dual antiplatelet therapy (DAPT), whether they have stable coronary artery disease, and do NOT have risk factors (eg, TIA or stroke, age 300 mg PO plus aspirin 81-325 mg for 1 dose on day before carotid artery stenting (CAS), then 75 mg/day PO plus aspirin 81-325 mg/day for at least 30 days after CAS Alternative: 300-600 mg PO once, then 75 mg/day for 4 days before CAS in combination with aspirin 81-325 mg/day CYP2C19 poor metabolizers associated with diminished antiplatelet response to clopidogrel; although hher-dose regimen (600 mg loading dose followed by 150 mg once daily) in poor metabolizers increases antiplatelet response, no appropriate dosing regimen for poor metabolizers has been established in clinical outcome trials Upper respiratory tract infection (8.7%) Chest pain (8.3%) Headache (7.6%) Flulike syndrome (7.5%) Arthralgia (6%) Pain (6%) Dizziness (6%) Diarrhea (4.5%) Rash (4.2%) Rhinitis (4.2%) Depression (3.6%) Urinary tract infection (3.1%) Blood and lymphatic system disorders: Agranulocytosis, aplastic anemia/pancytopenia, thrombotic thrombocytopenic purpura (TTP), acquired hemophilia A Eye disorders: Eye (conjunctival, ocular, retinal) bleeding Gastrointestinal disorders: Gastrointestinal and retroperitoneal hemorrhage with fatal outcome, colitis (including ulcerative or lymphocytic colitis), pancreatitis, stomatitis, gastric/duodenal ulcer, diarrhea General disorders and administration site condition: Fever, hemorrhage of operative wound Hepato-biliary disorders: Acute liver failure, hepatitis (non-infectious), abnormal liver function test Immune system disorders: Hypersensitivity reactions, anaphylactoid reactions, serum sickness Musculoskeletal, connective tissue and bone disorders: Musculoskeletal bleeding, myalgia, arthralgia, arthritis Nervous system disorders: Taste disorders, fatal intracranial bleeding, headache Psychiatric disorders: Confusion, hallucinations Respiratory, thoracic and mediastinal disorders: Bronchospasm, interstitial pneumonitis, respiratory tract bleeding, eosinophilic pneumonia Renal and urinary disorders: Increased creatinine levels Skin and subcutaneous tissue disorders: Maculopapular, erythematous, or exfoliative rash, urticaria, bullous dermatitis, eczema, toxic epidermal necrolysis, Stevens-Johnson syndrome, angioedema, drug-induced hypersensitivity syndrome, drug rash with eosinophilia and systemic symptoms (DRESS), erythema multiforme, skin bleeding, lichen planus, generalized pruritus, acute generalized exanthematous pustulosis (AGEP) Vascular disorders: Vasculitis, hypotension Clopidogrel's antiplatelet activity is dependent on conversion to an active metabolite by the cytochrome P450 (CYP) system, principally CYP2C19 Tests are available to identify patients who are CYP2C19 poor metabolizers Consider use of another platelet P2Y12 inhibitor in patients identified as CYP2C19 poor metabolizers Use with caution in patients with bleeding or platelet disorders Premature discontinuation increases risk of cardiovascular events; discontinue 5 days prior to elective surgery that has a major risk of bleeding Use caution in patients with atrial fibrillation; assess bleeding risk carefully; snificant increase in major bleeding events reported in patients receiving clopidogrel plus aspirin instead of aspirin alone Patients allergic to aspirin who are undergoing PCI; see American Heart Association (AHA)/American College of Chest Physicians (ACCP)/American College of Cardiology (ACC) recommendations Rare but potentially fatal thrombotic thrombocytopenic purpura associated with use Risk of bleeding with potentially fatal outcome Hepatic or renal impairment Allergic cross-reactivity including rash, angioedema, or hematologic reaction among thienopyridines (eg, ticlopidine, prasugrel) reported; evaluate patient for history of hypersensitivity Use caution in patients with severe hepatic or renal impairment Use caution or avoid in patients with hypersensitivity or hematologic reactions to previous thienopyridine use, including ticlopidine and prasugrel Use caution in patients receiving either anticoagulants, including heparin and warfarin, or other platelet aggregation inhibitors; risk of bleeding increases Premature interruption of therapy may result in stent thrombosis with subsequent fatal and nonfatal myocardial infarction; duration of therapy is determined by type of stent placed May increase risk of major hemorrhage in patients with recent lacunar stroke Pregnancy: There are no adequate and well-controlled studies in pregnant women; because animal reproduction studies are not always predictive of human response, clopidogrel should be used during pregnancy only if clearly needed Lactation: Not known whether drug is excreted in human milk; because many drugs are excreted in human milk and because of potential for serious adverse reactions in nursing infants from clopidogrel, a decision should be made whether to discontinue nursing or to discontinue drug, taking into account importance of drug to mother Metabolized in liver by hepatic CYP450 enzymes (in vitro by CYP3A4, CYP2C19 [predominantly], others) to generate active metabolite and also by esterase to generate inactive metabolite Metabolites: Thiol (active); further activation of thiol metabolite is required through hydrolysis via paraoxonase-1 (PON-1); allele variation of PON-1 may inhibit activation and increase risk for stent thrombosis The above information is provided for general informational and educational purposes only. See full prescribing information for PLAVIX. PLAVIX clopidogrel bisulfate tablets, for oral use Initial U. S. Approval 1997.
Plavix prescribing information - Pusat Jual Madu Plavix is the brand name form of the generic drug clopidogrel bisulfate, an anti-platelet medication that's used to prevent blood clots. Plavix stroke information. This information has performed on a larger way, anywhere prescribing that the themselves, but this growth.
Plavix prescribing information:
Rating: 94 / 100
Overall: 90 Rates